Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2004;109:1594-1602
Published online before print March 15, 2004, doi: 10.1161/01.CIR.0000124490.27666.B2
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
109/13/1594    most recent
01.CIR.0000124490.27666.B2v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mann, D. L.
Right arrow Articles by Fleming, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mann, D. L.
Right arrow Articles by Fleming, T.
Related Collections
Right arrow Congestive
Right arrow Other Treatment
Right arrow Growth factors/cytokines

(Circulation. 2004;109:1594-1602.)
© 2004 American Heart Association, Inc.


Clinical Investigation and Reports

Targeted Anticytokine Therapy in Patients With Chronic Heart Failure

Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)

Douglas L. Mann, MD; John J.V. McMurray, MD, FRCP, FESC; Milton Packer, MD; Karl Swedberg, MD, PhD, FESC; Jeffrey S. Borer, MD; Wilson S. Colucci, MD; Jacques Djian, MD, FESC; Helmut Drexler, MD; Arthur Feldman, MD, PhD; Lars Kober, MD; Henry Krum, MD, PhD, FRACP; Peter Liu, MD; Markku Nieminen, MD, PhD; Luigi Tavazzi, MD; Dirk Jan van Veldhuisen, MD, PhD; Anders Waldenstrom, MD, PhD; Marshelle Warren, MD; Arne Westheim, MD; Faiez Zannad, MD, PhD; Thomas Fleming, PhD

From the Winters Center for Heart Failure Research (D.L.M.), Baylor College of Medicine and the Houston VA, Houston, Tex; Department of Cardiology, Western Infirmary (J.J.V.M.), Glasgow, United Kingdom; Department of Medicine, University of Texas Dallas Southwestern Medical Center (M.P.), Dallas, Tex; Department of Medicine, Sahlgrenska University Hospital/Östra (K.S.), Göteborg, Sweden; Division of Cardiovascular Pathophysiology, Weill Medical College of Cornell University (J.S.B.), New York, NY; Division of Cardiology, Boston Medical Center (W.S.C.), Boston, Mass; Wyeth Research (J.D.), Paris, France; Medizinische Hochschule (H.D.), Hannover, Germany; Division of Cardiology, University of Pittsburgh Medical Center (A.F.), Pittsburgh, Pa; Gentofte Hospital/University of Copenhagen (L.K.), Department of Cardiology, Niels Andersens Vej, Denmark; Clinical Pharmacology Unit, Alfred Hospital (H.K.), Prahran, Victoria, Australia; The Toronto Hospital (P.L.), Cardiology Research, Toronto, Ontario, Canada; Division of Cardiology, Helsinki University Central Hospital (M.N.), Haartmaninkatu, Helsinki, Finland; Divisione di Cardiologia, Policlinico San Matteo-IRCCS (L.T.), Pavia, Italy; Academisch Ziekenhuis Groningen (D.J.v.V.), Cardio Research, GZ Groningen, The Netherlands; Department of Medicine, Umea University Hospital (A.W.), Umea, Sweden; Amgen Inc (M.W.), Thousand Oaks, Calif; Medicinsk Klinikk (A.W.), Hjertemedisinsk Avd, Ullevål Sykehus, Oslo, Norway; Centre d’Investigation Clinique (F.Z.), Hopital Jeanne d’Arc, Dommartin Les Toul Cedex, France; and Department of Biostatistics (T.F.), University of Washington, Seattle, Wash.

Correspondence to Douglas L Mann, MD, Winters Center for Heart Failure Research, MS 524, 6565 Fannin, Houston, TX 77030. E-mail dmann{at}bcm.tmc.edu

Received December 20, 2003; revision received January 26, 2004; accepted January 26, 2004.

Background— Studies in experimental models and preliminary clinical experience suggested a possible therapeutic role for the soluble tumor necrosis factor antagonist etanercept in heart failure.

Methods and Results— Patients with New York Heart Association class II to IV chronic heart failure and a left ventricular ejection fraction <=0.30 were enrolled in 2 clinical trials that differed only in the doses of etanercept used. In RECOVER, patients received placebo (n=373) or subcutaneous etanercept in doses of 25 mg every week (n=375) or 25 mg twice per week (n=375). In RENAISSANCE, patients received placebo (n=309), etanercept 25 mg twice per week (n=308), or etanercept 25 mg 3 times per week (n=308). The primary end point of each individual trial was clinical status at 24 weeks. Analysis of the effect of the 2 higher doses of etanercept on the combined outcome of death or hospitalization due to chronic heart failure from the 2 studies was also planned (RENEWAL). On the basis of prespecified stopping rules, both trials were terminated prematurely owing to lack of benefit. Etanercept had no effect on clinical status in RENAISSANCE (P=0.17) or RECOVER (P=0.34) and had no effect on the death or chronic heart failure hospitalization end point in RENEWAL (etanercept to placebo relative risk=1.1, 95% CI 0.91 to 1.33, P=0.33).

Conclusions— The results of RENEWAL rule out a clinically relevant benefit of etanercept on the rate of death or hospitalization due to chronic heart failure.


Key Words: heart failure • tumor necrosis factor • etanercept • cytokines




This article has been cited by other articles:


Home page
CirculationHome page
S. M. Dunlay, S. A. Weston, M. M. Redfield, J. M. Killian, and V. L. Roger
Tumor Necrosis Factor-{alpha} and Mortality in Heart Failure: A Community Study
Circulation, August 5, 2008; 118(6): 625 - 631.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. J. Finley IV, M. A. Konstam, and J. E. Udelson
Arginine Vasopressin Antagonists for the Treatment of Heart Failure and Hyponatremia
Circulation, July 22, 2008; 118(4): 410 - 421.
[Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
R. C Parish and J. D Evans
Inflammation in Chronic Heart Failure
Ann. Pharmacother., July 1, 2008; 42(7): 1002 - 1016.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Y.-M. Kang, Z.-H. Zhang, B. Xue, R. M. Weiss, and R. B. Felder
Inhibition of brain proinflammatory cytokine synthesis reduces hypothalamic excitation in rats with ischemia-induced heart failure
Am J Physiol Heart Circ Physiol, July 1, 2008; 295(1): H227 - H236.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
R. Bauer, G.A. MacGowan, A. Blain, K. Bushby, and V. Straub
Steroid treatment causes deterioration of myocardial function in the {delta}-sarcoglycan-deficient mouse model for dilated cardiomyopathy
Cardiovasc Res, June 30, 2008; (2008) cvn131v3.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
F. Leuschner, J. Li, S. Goser, L. Reinhardt, R. Ottl, P. Bride, J. Zehelein, G. Pfitzer, A. Remppis, E. Giannitsis, et al.
Absence of auto-antibodies against cardiac troponin I predicts improvement of left ventricular function after acute myocardial infarction
Eur. Heart J., June 13, 2008; (2008) ehn268v1.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
A. R. Kompa, F. See, D. A. Lewis, A. Adrahtas, D. M. Cantwell, B. H. Wang, and H. Krum
Long-Term but Not Short-Term p38 Mitogen-Activated Protein Kinase Inhibition Improves Cardiac Function and Reduces Cardiac Remodeling Post-Myocardial Infarction
J. Pharmacol. Exp. Ther., June 1, 2008; 325(3): 741 - 750.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
E. Braunwald
Biomarkers in Heart Failure
N. Engl. J. Med., May 15, 2008; 358(20): 2148 - 2159.
[Full Text] [PDF]


Home page
Circ. Res.Home page
M. Hori and K. Nishida
Toll-Like Receptor Signaling: Defensive or Offensive for the Heart?
Circ. Res., February 1, 2008; 102(2): 137 - 139.
[Full Text] [PDF]


Home page
ANN INTERN MEDHome page
N. E. Goldstein and D. Fischberg
Update in Palliative Medicine
Ann Intern Med, January 15, 2008; 148(2): 135 - 140.
[Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
P. Boor, K. Sebekova, T. Ostendorf, and J. Floege
Treatment targets in renal fibrosis
Nephrol. Dial. Transplant., December 1, 2007; 22(12): 3391 - 3407.
[Full Text] [PDF]


Home page
CirculationHome page
D. Seo and J. M. Hare
The Transforming Growth Factor-{beta}/Smad3 Pathway: Coming of Age as a Key Participant in Cardiac Remodeling
Circulation, November 6, 2007; 116(19): 2096 - 2098.
[Full Text] [PDF]


Home page
HypertensionHome page
I. H. Zucker, J. F. Hackley, K. G. Cornish, B. A. Hiser, N. R. Anderson, R. Kieval, E. D. Irwin, D. J. Serdar, J. D. Peuler, and M. A. Rossing
Chronic Baroreceptor Activation Enhances Survival in Dogs With Pacing-Induced Heart Failure
Hypertension, November 1, 2007; 50(5): 904 - 910.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
W G Dixon and D P M Symmons
What effects might anti-TNF{alpha} treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNF{alpha} in cardiovascular pathophysiology
Ann Rheum Dis, September 1, 2007; 66(9): 1132 - 1136.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
D. Mozaffarian, S. D. Anker, I. Anand, D. T. Linker, M. D. Sullivan, J. G.F. Cleland, P. E. Carson, A. P. Maggioni, D. L. Mann, B. Pitt, et al.
Prediction of Mode of Death in Heart Failure: The Seattle Heart Failure Model
Circulation, July 24, 2007; 116(4): 392 - 398.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Y. Monden, T. Kubota, T. Inoue, T. Tsutsumi, S. Kawano, T. Ide, H. Tsutsui, and K. Sunagawa
Tumor necrosis factor-{alpha} is toxic via receptor 1 and protective via receptor 2 in a murine model of myocardial infarction
Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H743 - H753.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
A. Guggilam, M. Haque, E. K. Kerut, E. McIlwain, P. Lucchesi, I. Seghal, and J. Francis
TNF-{alpha} blockade decreases oxidative stress in the paraventricular nucleus and attenuates sympathoexcitation in heart failure rats
Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H599 - H609.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
P. C. Schulze
Chromogranin A: friend or foe of the failing myocardium?
Eur. Heart J., May 1, 2007; 28(9): 1052 - 1053.
[Full Text] [PDF]


Home page
Cardiovasc ResHome page
Y. Monden, T. Kubota, T. Tsutsumi, T. Inoue, S. Kawano, N. Kawamura, T. Ide, K. Egashira, H. Tsutsui, and K. Sunagawa
Soluble TNF receptors prevent apoptosis in infiltrating cells and promote ventricular rupture and remodeling after myocardial infarction
Cardiovasc Res, March 1, 2007; 73(4): 794 - 805.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
K. K. Khush, D. D. Waters, V. Bittner, P. C. Deedwania, J. J.P. Kastelein, S. J. Lewis, and N. K. Wenger
Effect of High-Dose Atorvastatin on Hospitalizations for Heart Failure: Subgroup Analysis of the Treating to New Targets (TNT) Study
Circulation, February 6, 2007; 115(5): 576 - 583.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
S. von Haehling, W. Doehner, and S. D Anker
Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure
Cardiovasc Res, January 15, 2007; 73(2): 298 - 309.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
A. Skyschally, P. Gres, S. Hoffmann, M. Haude, R. Erbel, R. Schulz, and G. Heusch
Bidirectional Role of Tumor Necrosis Factor-{alpha} in Coronary Microembolization: Progressive Contractile Dysfunction Versus Delayed Protection Against Infarction
Circ. Res., January 5, 2007; 100(1): 140 - 146.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
A. Csiszar, N. Labinskyy, K. Smith, A. Rivera, Z. Orosz, and Z. Ungvari
Vasculoprotective Effects of Anti-Tumor Necrosis Factor-{alpha} Treatment in Aging
Am. J. Pathol., January 1, 2007; 170(1): 388 - 698.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
A. Linde, D. Mosier, F. Blecha, and T. Melgarejo
Innate immunity and inflammation - New frontiers in comparative cardiovascular pathology
Cardiovasc Res, January 1, 2007; 73(1): 26 - 36.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M. Bellahcene, S. Jacquet, X. B. Cao, M. Tanno, R. S. Haworth, J. Layland, A. M. Kabir, M. Gaestel, R. J. Davis, R. A. Flavell, et al.
Activation of p38 Mitogen-Activated Protein Kinase Contributes to the Early Cardiodepressant Action of Tumor Necrosis Factor
J. Am. Coll. Cardiol., August 1, 2006; 48(3): 545 - 555.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
C. B. Granger and J. J.V. McMurray
Using Measures of Disease Progression to Determine Therapeutic Effect: A Sirens' Song
J. Am. Coll. Cardiol., August 1, 2006; 48(3): 434 - 437.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. Wang, B. M. Tsai, P. R. Crisostomo, and D. R. Meldrum
Tumor Necrosis Factor Receptor 1 Signaling Resistance in the Female Myocardium During Ischemia
Circulation, July 4, 2006; 114(1_suppl): I-282 - I-289.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
K. Kaur, A. K. Sharma, and P. K. Singal
Significance of changes in TNF-{alpha} and IL-10 levels in the progression of heart failure subsequent to myocardial infarction
Am J Physiol Heart Circ Physiol, July 1, 2006; 291(1): H106 - H113.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
P. Jhund and J. J.V. McMurray
Does Aspirin Reduce the Benefit of an Angiotensin-Converting Enzyme Inhibitor?: Choosing Between the Scylla of Observational Studies and the Charybdis of Subgroup Analysis
Circulation, June 6, 2006; 113(22): 2566 - 2568.
[Full Text] [PDF]


Home page
Eur Heart J SupplHome page
P. Lechat
The evolution of heart failure management over recent decades: from CONSENSUS to CIBIS
Eur. Heart J. Suppl., June 1, 2006; 8(suppl_C): C5 - C12.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
E. A. Jankowska, P. Ponikowski, M. F. Piepoli, W. Banasiak, S. D. Anker, and P. A. Poole-Wilson
Autonomic imbalance and immune activation in chronic heart failure - Pathophysiological links
Cardiovasc Res, June 1, 2006; 70(3): 434 - 445.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
J. E Morley, D. R Thomas, and M.-M. G Wilson
Cachexia: pathophysiology and clinical relevance.
Am. J. Clinical Nutrition, April 1, 2006; 83(4): 735 - 743.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
W. C. Levy, D. Mozaffarian, D. T. Linker, S. C. Sutradhar, S. D. Anker, A. B. Cropp, I. Anand, A. Maggioni, P. Burton, M. D. Sullivan, et al.
The Seattle Heart Failure Model: Prediction of Survival in Heart Failure
Circulation, March 21, 2006; 113(11): 1424 - 1433.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
P. Carson, I. Anand, C. O'Connor, B. Jaski, J. Steinberg, A. Lwin, J. Lindenfeld, J. Ghali, J. H. Barnet, A. M. Feldman, et al.
Mode of Death in Advanced Heart Failure: The Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) Trial
J. Am. Coll. Cardiol., December 20, 2005; 46(12): 2329 - 2334.
[Abstract] [Full Text] [PDF]


Home page
Rheumatology (Oxford)Home page
F. C. Hall and N. Dalbeth
Disease modification and cardiovascular risk reduction: two sides of the same coin?
Rheumatology, December 1, 2005; 44(12): 1473 - 1482.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
S. Grundmann, I. Hoefer, S. Ulusans, N. van Royen, S. H. Schirmer, C. K. Ozaki, C. Bode, J. J. Piek, and I. Buschmann
Anti-tumor necrosis factor-{alpha} therapies attenuate adaptive arteriogenesis in the rabbit
Am J Physiol Heart Circ Physiol, October 1, 2005; 289(4): H1497 - H1505.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. L. Clark and J. G.F. Cleland
Anemia and Chronic Heart Failure: Are We Asking the Right Questions?
Circulation, September 20, 2005; 112(12): 1681 - 1683.
[Full Text] [PDF]


Home page
LupusHome page
P Sarzi-Puttini, F Atzeni, A Doria, L Iaccarino, and M Turiel
Tumor necrosis factor-a, biologic agents and cardiovascular risk
Lupus, September 1, 2005; 14(9): 780 - 784.
[Abstract] [PDF]


Home page
Circ. Res.Home page
Z. Kassiri, G. Y. Oudit, O. Sanchez, F. Dawood, F. F. Mohammed, R. K. Nuttall, D. R. Edwards, P. P. Liu, P. H. Backx, and R. Khokha
Combination of Tumor Necrosis Factor-{alpha} Ablation and Matrix Metalloproteinase Inhibition Prevents Heart Failure After Pressure Overload in Tissue Inhibitor of Metalloproteinase-3 Knock-Out Mice
Circ. Res., August 19, 2005; 97(4): 380 - 390.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
D. Mancini and D. Burkhoff
Mechanical Device-Based Methods of Managing and Treating Heart Failure
Circulation, July 19, 2005; 112(3): 438 - 448.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
D. Gurantz, A. Yndestad, B. Halvorsen, O. V. Lunde, J. H. Omens, T. Ueland, P. Aukrust, C. D. Moore, J. Kjekshus, and B. H. Greenberg
Etanercept or intravenous immunoglobulin attenuates expression of genes involved in post-myocardial infarction remodeling
Cardiovasc Res, July 1, 2005; 67(1): 106 - 115.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
D. Burkhoff and S. A. Ben-Haim
Nonexcitatory electrical signals for enhancing ventricular contractility: rationale and initial investigations of an experimental treatment for heart failure
Am J Physiol Heart Circ Physiol, June 1, 2005; 288(6): H2550 - H2556.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
E. P. Havranek
Improving the Outcomes of Heart Failure Care: Putting Technology Second
J. Am. Coll. Cardiol., May 17, 2005; 45(10): 1665 - 1666.
[Full Text] [PDF]


Home page
Physiol. GenomicsHome page
M. M. Kittleson, K. M. Minhas, R. A. Irizarry, S. Q. Ye, G. Edness, E. Breton, J. V. Conte, G. Tomaselli, J. G. N. Garcia, and J. M. Hare
Gene expression analysis of ischemic and nonischemic cardiomyopathy: shared and distinct genes in the development of heart failure
Physiol Genomics, May 11, 2005; 21(3): 299 - 307.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
P J Mease and C E Antoni
Psoriatic arthritis treatment: biological response modifiers
Ann Rheum Dis, March 1, 2005; 64(suppl_2): ii78 - ii82.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
A. T. Yan, R. T. Yan, and P. P. Liu
Narrative Review: Pharmacotherapy for Chronic Heart Failure: Evidence from Recent Clinical Trials
Ann Intern Med, January 18, 2005; 142(2): 132 - 145.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
S. Lecour, L. Rochette, and L. Opie
Free radicals trigger TNF{alpha}-induced cardioprotection
Cardiovasc Res, January 1, 2005; 65(1): 239 - 243.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J. J.V. McMurray and M. A. Pfeffer
The year in heart failure
J. Am. Coll. Cardiol., December 21, 2004; 44(12): 2398 - 2405.
[Full Text] [PDF]


Home page
CirculationHome page
M. Sun, F. Dawood, W.-H. Wen, M. Chen, I. Dixon, L. A. Kirshenbaum, and P. P. Liu
Excessive Tumor Necrosis Factor Activation After Infarction Contributes to Susceptibility of Myocardial Rupture and Left Ventricular Dysfunction
Circulation, November 16, 2004; 110(20): 3221 - 3228.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
U. C. Sharma, S. Pokharel, T. J. van Brakel, J. H. van Berlo, J. P.M. Cleutjens, B. Schroen, S. Andre, H. J.G.M. Crijns, H.-J. Gabius, J. Maessen, et al.
Galectin-3 Marks Activated Macrophages in Failure-Prone Hypertrophied Hearts and Contributes to Cardiac Dysfunction
Circulation, November 9, 2004; 110(19): 3121 - 3128.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
G. Torre-Amione, F. Sestier, B. Radovancevic, and J. Young
Effects of a novel immune modulation therapy in patients with advanced chronic heart failure: Results of a randomized, controlled, phase II trial
J. Am. Coll. Cardiol., September 15, 2004; 44(6): 1181 - 1186.
[Abstract] [Full Text] [PDF]


Home page
Evid. Based Med.Home page
Other articles noted
Evid. Based Med., September 1, 2004; 9(5): e5 - e5.
[Full Text] [PDF]